Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on The Nasdaq Global Select Market under the symbol “BCEL.”

Atreca is a biopharmaceutical company utilizing their differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct them to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Xin (Anita) Guo and Benson Richards. Partner Rachel D. Kleinberg provided tax advice. Associates Daniel F. Forester and Daniel P. Kearney provided intellectual property and technology advice. Associates Travis Triano and John G. Curran provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post